Starpharma EV / EBITDA
Cos'è EV / EBITDA di Starpharma?
EV / EBITDA di Starpharma Holdings Limited è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su ASX rispetto a Starpharma
Cosa fa Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Aziende con ev / ebitda simili a Starpharma
- AuMake International ha EV / EBITDA di N/A
- Hydoo International ha EV / EBITDA di N/A
- Damara Gold ha EV / EBITDA di N/A
- Kairos Minerals ha EV / EBITDA di N/A
- TVI Pacific ha EV / EBITDA di N/A
- Aurion Resources ha EV / EBITDA di N/A
- Starpharma ha EV / EBITDA di N/A
- Diagnostic Medical Systems S.A ha EV / EBITDA di N/A
- Xelpmoc Design and Tech ha EV / EBITDA di N/A
- Just Plc ha EV / EBITDA di N/A
- M&L ha EV / EBITDA di N/A
- Takeaway.com NV ha EV / EBITDA di N/A
- Just Eat Takeaway.com N.V ha EV / EBITDA di N/A